Chemotherapy-induced Nausea and Vomiting Drugs Market Size, Share, Trends, Growth Outlook

Chemotherapy-induced Nausea and Vomiting Drugs Market is estimated to increase at a growth rate of 6.2% CAGR over the forecast period from 2024 to 2030.

The global Chemotherapy-induced Nausea and Vomiting Drugs Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Acute emesis, Delayed emesis, Anticipatory emesis, Refractory emesis), By Therapy (Nk-1 receptor antagonist, Serotonin receptor antagonist, Others), By Population (Children, Adults), By Drug (Branded, Generic), By Route of Administration (Oral, Parenteral), By End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others).

An Introduction to Chemotherapy-induced Nausea and Vomiting Drugs Market in 2024

The Chemotherapy-induced Nausea and Vomiting Drugs Market focuses on pharmaceuticals and medications prescribed to manage nausea and vomiting symptoms associated with cancer chemotherapy treatments. These drugs include antiemetics, serotonin receptor antagonists, corticosteroids, and neurokinin-1 receptor antagonists, aiming to improve patients' quality of life during cancer therapy. In 2024, this market emphasizes novel drug formulations, personalized antiemetic regimens, supportive care strategies, and patient education initiatives, enhancing symptom control and treatment adherence in oncology settings.

Chemotherapy-induced Nausea and Vomiting Drugs Market Competitive Landscape

The global Chemotherapy-induced Nausea and Vomiting Drugs Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Chemotherapy-induced Nausea and Vomiting Drugs Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Chemotherapy-induced Nausea and Vomiting Drugs Industry include- Baxter, Eisai, Helsinn Holding, Helsinn Holding S.A., Heron Therapeutics, Mundipharma, Novartis AG, Orchid Healthcare, ProStrakan, Qilu Pharma, F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd, Tesaro.

Chemotherapy induced Nausea and Vomiting Drugs Market Trend: Advancements in Antiemetic Therapy

A significant trend in the Chemotherapy-induced Nausea and Vomiting (CINV) Drugs market is the continuous advancements in antiemetic therapy, aimed at providing more effective and personalized management of CINV. Pharmaceutical companies are investing in the development of novel antiemetic agents with improved efficacy, reduced side effects, and longer duration of action to address the diverse needs of cancer patients undergoing chemotherapy. Additionally, there is a growing focus on combination therapies and multimodal approaches, incorporating various classes of antiemetics targeting different neurotransmitter pathways involved in CINV, thereby enhancing treatment outcomes and patient satisfaction.

Chemotherapy induced Nausea and Vomiting Drugs Market Driver: Increasing Incidence of Chemotherapy-induced Nausea and Vomiting

The primary driver for the Chemotherapy-induced Nausea and Vomiting (CINV) Drugs market is the rising incidence of CINV among cancer patients undergoing chemotherapy treatment. Despite advances in chemotherapy regimens and supportive care, CINV remains one of the most distressing and debilitating side effects of cancer treatment, significantly impacting patients' quality of life and treatment adherence. As the number of cancer diagnoses continues to increase globally and chemotherapy remains a cornerstone of cancer therapy, there is a growing demand for effective antiemetic medications to prevent and manage CINV symptoms, driving market growth.

Chemotherapy induced Nausea and Vomiting Drugs Market Opportunity: Development of Targeted Therapies and Personalized Treatment Approaches

An opportunity for market expansion in the Chemotherapy-induced Nausea and Vomiting (CINV) Drugs segment lies in the development of targeted therapies and personalized treatment approaches tailored to individual patient characteristics and chemotherapy regimens. With advances in pharmacogenomics and precision medicine, there is a growing recognition of the interindividual variability in CINV susceptibility and response to antiemetic medications. Pharmaceutical companies can capitalize on this opportunity by investing in the research and development of biomarker-based predictive tests to identify patients at high risk of CINV and guide the selection of optimal antiemetic therapies. Additionally, exploring novel drug targets and innovative delivery mechanisms, such as extended-release formulations and transdermal patches, can further enhance the efficacy and convenience of CINV treatment, addressing unmet needs in the oncology supportive care market. By offering personalized and targeted solutions for CINV management, companies can differentiate themselves in the competitive landscape and improve patient outcomes.

Market Share Analysis: NK-1 Receptor Antagonist Drugs is the fastest growing segment in the Chemotherapy induced Nausea and Vomiting Drugs industry

Among chemotherapy-induced nausea and vomiting (CINV) drugs, NK-1 receptor antagonist drugs are experiencing rapid growth. NK-1 receptor antagonists are a class of medications used to prevent and manage nausea and vomiting associated with chemotherapy, particularly acute and delayed emesis, which are common side effects of cancer treatment. These drugs work by blocking the action of substance P, a neurotransmitter involved in the emetic response pathway. NK-1 receptor antagonists have demonstrated superior efficacy in preventing CINV when used in combination with other antiemetic agents, such as serotonin receptor antagonists and corticosteroids. As healthcare providers prioritize the management of CINV to improve patient comfort and adherence to chemotherapy regimens, the demand for NK-1 receptor antagonist drugs is rapidly increasing. Moreover, advancements in drug formulations and administration methods, including oral and parenteral routes, enhance patient convenience and compliance. Hospitals, specialty clinics, and home healthcare settings are witnessing a surge in the utilization of NK-1 receptor antagonist drugs, reflecting their growing importance in supportive cancer care. As the prevalence of cancer continues to rise and the demand for effective CINV management grows, NK-1 receptor antagonist drugs are expected to maintain their rapid growth trajectory, offering significant benefits to cancer patients undergoing chemotherapy.

Chemotherapy-induced Nausea and Vomiting Drugs Market Segmentation

By Type
Acute emesis
Delayed emesis
Anticipatory emesis
Refractory emesis
By Therapy
Nk-1 receptor antagonist
Serotonin receptor antagonist
Others
By Population
Children
Adults
By Drug
Branded
Generic
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Chemotherapy-induced Nausea and Vomiting Drugs Companies

Baxter
Eisai
Helsinn Holding
Helsinn Holding S.A.
Heron Therapeutics
Mundipharma
Novartis AG
Orchid Healthcare
ProStrakan
Qilu Pharma
F. Hoffmann-La Roche Ltd
Sun Pharmaceutical Industries Ltd
Tesaro
* List not Exhaustive

Reasons to Buy the Chemotherapy-induced Nausea and Vomiting Drugs Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Chemotherapy-induced Nausea and Vomiting Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Chemotherapy-induced Nausea and Vomiting Drugs Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Chemotherapy-induced Nausea and Vomiting Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 Chemotherapy-induced Nausea and Vomiting Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 Chemotherapy-induced Nausea and Vomiting Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 Chemotherapy-induced Nausea and Vomiting Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 Chemotherapy-induced Nausea and Vomiting Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Chemotherapy-induced Nausea and Vomiting Drugs Industry
4.2 Key Market Trends in Chemotherapy-induced Nausea and Vomiting Drugs Industry
4.3 Potential Opportunities in Chemotherapy-induced Nausea and Vomiting Drugs Industry
4.4 Key Challenges in Chemotherapy-induced Nausea and Vomiting Drugs Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Outlook by Segments
7.1 Chemotherapy-induced Nausea and Vomiting Drugs Market Outlook by Segments, $ Million, 2021- 2030
By Type
Acute emesis
Delayed emesis
Anticipatory emesis
Refractory emesis
By Therapy
Nk-1 receptor antagonist
Serotonin receptor antagonist
Others
By Population
Children
Adults
By Drug
Branded
Generic
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
8 North America Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis and Outlook To 2030
8.1 Introduction to North America Chemotherapy-induced Nausea and Vomiting Drugs Markets in 2024
8.2 North America Chemotherapy-induced Nausea and Vomiting Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Chemotherapy-induced Nausea and Vomiting Drugs Market size Outlook by Segments, 2021-2030
By Type
Acute emesis
Delayed emesis
Anticipatory emesis
Refractory emesis
By Therapy
Nk-1 receptor antagonist
Serotonin receptor antagonist
Others
By Population
Children
Adults
By Drug
Branded
Generic
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
9 Europe Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis and Outlook To 2030
9.1 Introduction to Europe Chemotherapy-induced Nausea and Vomiting Drugs Markets in 2024
9.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Chemotherapy-induced Nausea and Vomiting Drugs Market Size Outlook by Segments, 2021-2030
By Type
Acute emesis
Delayed emesis
Anticipatory emesis
Refractory emesis
By Therapy
Nk-1 receptor antagonist
Serotonin receptor antagonist
Others
By Population
Children
Adults
By Drug
Branded
Generic
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
10 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Markets in 2024
10.2 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Market size Outlook by Segments, 2021-2030
By Type
Acute emesis
Delayed emesis
Anticipatory emesis
Refractory emesis
By Therapy
Nk-1 receptor antagonist
Serotonin receptor antagonist
Others
By Population
Children
Adults
By Drug
Branded
Generic
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
11 South America Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis and Outlook To 2030
11.1 Introduction to South America Chemotherapy-induced Nausea and Vomiting Drugs Markets in 2024
11.2 South America Chemotherapy-induced Nausea and Vomiting Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Chemotherapy-induced Nausea and Vomiting Drugs Market size Outlook by Segments, 2021-2030
By Type
Acute emesis
Delayed emesis
Anticipatory emesis
Refractory emesis
By Therapy
Nk-1 receptor antagonist
Serotonin receptor antagonist
Others
By Population
Children
Adults
By Drug
Branded
Generic
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
12 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Markets in 2024
12.2 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Market size Outlook by Segments, 2021-2030
By Type
Acute emesis
Delayed emesis
Anticipatory emesis
Refractory emesis
By Therapy
Nk-1 receptor antagonist
Serotonin receptor antagonist
Others
By Population
Children
Adults
By Drug
Branded
Generic
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Baxter
Eisai
Helsinn Holding
Helsinn Holding S.A.
Heron Therapeutics
Mundipharma
Novartis AG
Orchid Healthcare
ProStrakan
Qilu Pharma
F. Hoffmann-La Roche Ltd
Sun Pharmaceutical Industries Ltd
Tesaro
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Acute emesis
Delayed emesis
Anticipatory emesis
Refractory emesis
By Therapy
Nk-1 receptor antagonist
Serotonin receptor antagonist
Others
By Population
Children
Adults
By Drug
Branded
Generic
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Specialty Clinics
Home Healthcare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others